Gut microbiota is important for our health and well-being, but when its composition is disrupted, it can induce or perpetuate several chronic inflammatory disorders, including inflammatory bowel diseases (IBD). The mechanisms which distinguish protective microbes from the deleterious or indifferent ones are largely unknown. The aim of this thesis was to study the interaction of the immune system with microbes that have different relationships to IBD pathogenesis. Escherichia coli is a predominant aerobic microorganism of the gastrointestinal tract. This species includes microbes implicated in induction of IBD as well as in its therapy. Four E. coli strains with different relations to IBD were selected for our experiments: E. coli Nissle 1917 (EcN), which has been successfully used in IBD therapy, E. coli strains LF82 and p19A, which have been implicated in the pathogenesis of IBD, and E. coli strain K6, which has neither been implicated in pathogenesis nor in protection from this disease. The experiments were performed both with living bacteria and inactivated ones. As the mode of inactivation may change the microbial antigenic structure, we measured how different methods of inactivation, i.e. 1% formaldehyde, exposure to heat or UV irradiation, influence the microbe's immunogenicity. First, we...

Iron deficiency anemia (IDA) is a common extra-intestinal manifestation of inflammatory bowel disease (IBD). It is particularly common in the pediatric population, with 40-60% of pediatric patients with IBD meeting criteria for anemia (Aljomah et al, 2018). A number of studies have examined the use of both IV and oral iron treatments to treat anemia in IBD, but few have examined the safety and efficacy of these treatments in children and how they impact a patient’s health-related quality of life. We conducted a prospective cohort study of 79 pediatric patients admitted to Boston Children’s Hospital for management of their IBD. 48 of these patients received IV iron, 13 received oral iron, and 12 were not treated with either. Treatment with IV iron resulted in a statistically significant increase in hemoglobin of 1.75g/dL+/-1.4g/dL (mean +/- SD) from admission to the time of their first post-discharge visit (p=0.0001). Prescription of oral iron at the time of discharge did not result in a significant increase in hemoglobin over the same interval (p=0.481). Though there was a positive trend, IV iron treatment did not result in a significant change in health-related quality of life (HRQOL) measurements as measured by the IMPACT-III questionnaire (p=0.06). Our study suggests that IDA is common in patients admitted for management of their IBD, IV iron is more efficacious in raising hemoglobin, and that larger studies will be needed to more fully demonstrate the impact of effective iron repletion on overall quality of life in these patients.

Att drabbas av en kronisk inflammatorisk tarmsjukdom är på många sätt en omvälvande upplevelse. Sjukdomen innebär både fysiska och psykiska förändringar som begränsar patienten i det dagliga livet. Sjukdomen debuterar ofta i tidig ålder och kommer i skov vilket för patienten innebär ett långdraget sjukdomsförlopp och återkommande kontakter med hälso-sjukvården. Alla dessa förändringar leder till en förändrad livssituation, en sämre livskvalitet och ett ökat lidande för den drabbade. Det är viktigt att man som sjuksköterska har kunskap och förståelse om hur sjukdomen påvekar patientens livssituation för att minska risken för försämrad livskvalitet och lidande.Studiens syfte är att beskriva patientens upplevelse av att leva med en inflammatorisk tarmsjukdom.Denna kvalitativa litteraturstudie utgår ifrån sju vetenskapliga artiklar baserade på män och kvinnors upplevelser av inflammatorisk tarmsjukdom. Artiklarna granskades enligt Evans (2002) modell och sammanställdes till tre huvudteman med nio underteman.Resultatet visar att patienter med inflammatorisk tarmsjukdom begränsas i sitt dagliga liv vilket resulterar i sämre livskvalitet och psykiskt lidande. Det var sjukdomens symtom, läkemedelsbiverkningarna och skammen över de kroppsliga och sociala förändringar som följde med dessa som verkade begränsande. Resultatet pekar även på att patienterna på grund av sin sjukdom kände sig avvikande från normen och annorlunda i jämförelse med andra människor vilket bidrog till social isolering och utanförskap. Resultatet tyder på att patienterna ansåg att de hade bristfällig kunskap om sin sjukdom och de uttryckte ett behov av information och stöd från vårdpersonal. Vi anser att sjuksköterskan genom att se till den enskilda patientens behov och känslor kan minska lidandet och öka livskvaliteten. / Program: Sjuksköterskeutbildning

There is an unmet need for novel biomarker discovery in Inflammatory Bowel Diseases (IBD) to aid clinical management in several clinical settings including diagnosis and prognosis. With an ever-advancing repertoire of biological therapies on the horizon, it is important to personalise treatments at an early stage. The aim of this thesis is to explore the clinical utility of novel blood-based biomarkers in diagnosis, disease classification and prognosis in 2 cohorts: newly diagnosed IBD and acute severe colitis. Investigating the circulating methylome, 290 probes exhibited Holm significant IBD-associated methylation differences, including VMP1/MIR21 (p=7.5×10-14) and RPS6KA2 (1.1×10-19) and were consistent within the European cohort. 11 Differentially methylated positions (DMPs) predicted treatment escalation after Holm adjustment (top probe p=0.003). A panel of 6 probes identified 2 patient subgroups that have significantly different disease courses (Hazard Ratio (HR) 10.5, 95%CI: 4.3-25.6; logrank p=1.5×10-24). The 6 probe marker outperformed conventional biomarkers in predicting treatment escalation (hsCRP > 4mg/L, HR 3.2(1.7-5.8), logrank p=0.0004 and Alb < 36g/L, HR 2.9(1.5-5.6), p=0.0001). Within the same cohort, a novel proximity extension assay (PEA) was then utilised to identify novel diagnostic and prognostic protein markers. 61 proteins were significantly associated with IBD including MMP12 (Holm-adjusted p=4.1×10-26). A total of 9 proteins predicted disease course in this cohort. Using a panel of 7 randomly selected top prognostic probes, 2 patient groups were identified that had significantly different disease courses: logrank p=2.2×10-10, HR 5.6(2.0-15.6), outperforming conventional biomarkers in predicting treatment escalation (hsCRP > 4mg/L, HR 3.2(1.7- 5.8), logrank p=0.0003 and Alb < 36g/L, HR 2.7(1.4-5.2), p=0.0004). In a subcohort, serum calprotectin (SC) and conventional blood markers were investigated for their utility in diagnosis and prognosis in IBD. SC performed at par with CRP at differentiating IBD from controls with an area under the curve (AUC) of 0.87 (CI 0.81-0.92). For prognostication, both albumin and SC remained significant predictors of treatment escalation in IBD (logrank test p=5.1×10-5). MicroRNAs (miRNA) are small non-coding nucleic acids that have the capacity to modulate gene expression. Using small RNA sequencing in acute severe colitis (ASUC) and healthy controls (HC), 10 serum-based miRNA markers were significantly associated with acute severe colitis, including miR-30a-5p. Validating the findings using qPCR, miR-30a-5p was downregulated in ASUC (p=0.003). Furthermore, miR30a-5p remained a significant predictor of eventual colectomy in acute colitis (logrank test p=0.0014). These data highlight the translational potential for methylation, miRNA and proteomic biomarkers in diagnosing and prognosticating in IBD.

Epigenetic alterations including DNA methylation and microRNAs may provide important insights into gene-environment interaction in complex immune diseases such as inflammatory bowel disease (IBD). An integrative genome-wide approach was used to analyse whole blood genetic, DNA methylation and gene expression data in 240 newly diagnosed IBD patients and 190 controls. Using the Illumina 450k array, differences in whole blood DNA methylation were observed in IBD cases versus controls including 439 differentially methylated positions (DMPs) and 5 differentially methylated regions (DMRs). The top DMP (RPS6KA2, discovery Holm adjusted p=1.22×10-16, replication p=1×10-9) and DMRs (VMP1, ITGB2, TXK) were replicated in an independent cohort using pyrosequencing. Paired genetic and epigenetic data allowed the identification of methylation quantitative trait loci (meQTL); two of the five DMRs (VMP1, ITGB2) demonstrated significant association with genetic polymorphisms. Methylation in the VMP1/microRNA-21 region was significantly associated with two single nucleotide polymorphisms (cg18942579 -rs10853015 [meQTL FDR adjusted p=9.4 × 10-5], cg16936953 - rs8078424 [meQTL FDR adjusted p=8.8 × 10-5]), both of which are in linkage disequilibrium with a known IBD susceptibility variant (rs1292053). Separated leukocyte methylation data highlight the cell type of origin of epigenetic signals seen in whole blood. IBD-associated hypermethylation within the TXK gene transcription start-site negatively correlated with gene expression in whole blood and CD8+ T-cells, but not other cell types, highlighting that cell-specificity and gene location-specificity of DNA methylation change is critical when associating methylation and gene expression. These data offer significant translational potential as diagnostic biomarkers. Least absolute shrinkage and selection operator (lasso) modelling identified 30 methylation probes can be used to accurately discriminate IBD cases from controls (Area under receiver operating characteristic curve = 0.898, sensitivity = 90.6%, specificity = 84.7%). MicroRNAs (miRNA) are small non-coding nucleic acids that have the capacity to modulate gene expression. MiRNAs have been increasingly implicated in many of the important IBD pathogenic pathways including autophagy, intestinal epithelial barrier integrity and the Th17 pathway. In common with all epigenetic mechanisms, miRNA expression is dynamic and cell-specific. Small RNA sequencing (RNA-seq) was performed on RNA extracted from CD14+, CD4+ and CD8+ cells isolated from 8 newly diagnosed cases of ileal or ileocolonic CD and 8 age and sex matched controls. There was a median of 2.4 million reads per sample (range 132,800-12.8 million reads per sample). One microRNA was differentially expressed in CD compared with controls (hsa-miR-503-5p log fold change = 0.7, FDR adjusted p = 9.1 × 10-5) in CD4+ lymphocytes, however this finding did not remain significant when alternative normalisation methods were used. The small number of cases used in microRNA analyses raises the possibility of both type I and II error, and limits the ability to draw firm conclusion from this series of experiments. Site-specific differences in DNA methylation in IBD relate to underlying genotype and associate with cell-specific alteration in gene expression. This is the most detailed characterisation of the epigenome carried out in IBD to date. The findings strongly validate this approach in complex disease, are replicable, and provide clear translational opportunities.

L’étiologie exacte des maladies inflammatoires chroniques de l’intestin (MICI) reste actuellement méconnue. Mais un déséquilibre de la flore bactérienne, plus connu sous le nom de dysbiose et se traduisant par une augmentation de bactéries potentiellement pathogènes versus une diminution de bactéries bénéfiques, est démontré en permanence. De précédentes études ont permis de mettre en évidence la présence de souches pathogènes d’E. coli chez les patients atteints de la maladie de Crohn (MC). Ces souches appartiennent au pathovar Adherent Invasive E. coli (AIEC) et sont caractérisées par leur capacité à adhérer et à envahir les cellules épithéliales intestinales, à survivre et à se multiplier dans les macrophages en induisant une synthèse intense de TNF. La mise en évidence de ce pathovar a essentiellement été réalisée sur des biopsies de patients présentant une MC. Et bien que les mécanismes de pathogénicité et de virulence de la souche AIEC soient clairement déterminés, il n’existe pas d’études approfondies sur la prévalence des AIEC au niveau des matières fécales chez les patients atteints de MICI en comparaison à des individus sains. Ainsi, ce projet de thèse s’inscrit dans une meilleure compréhension de l’implication de ce pathovar AIEC dans les MICI au niveau luminal. Cette thèse cible différents points: prévalence et détection des AIEC, leur proportion relative par rapport à la flore E. coli totale, leur capacité d'invasion, leur phylogroupe ainsi que leur transmissibilité. A l’issue de ce travail, nous montrons que les AIEC sont retrouvés au niveau luminal chez les patients atteints de la MC mais également chez les patients présentant une rectocolite hémorragique, avec une détection des AIEC chez 33% et 2% respectivement. En outre, ces études ont permis de montrer une prévalence plus forte de ce pathovar dans les matières fécales d’individus sains (51%) en comparaison aux patients atteints de MICI. Et lorsque les AIEC sont présents, que ce soit chez les patients atteints de MICI et chez les témoins, ils représentent en moyenne 20 à 30% de la flore E. coli. Nous avons également pu montrer qu’il n’existe pas de différences significatives des scores d’invasion des isolats AIEC chez les patients atteints de MICI et chez les sujets sains. Certaines souches d’AIEC, isolées chez les patients atteints de MC et chez les sujets sains, ont été caractérisées génétiquement par la technique d’électrophorèse sur gel en champ pulsé. Sur ces souches, différents profils génétiques ont été obtenus attestant de la forte variabilité intra- et interindivuelle des AIEC. En conclusion, les AIEC, au vue de leur forte prévalence chez des sujets en bonne santé, seraient plutôt à reconsidérer comme des pathobionts ce qui définit un symbionte pouvant acquérir des propriétés virulentes chez un hôte prédisposé génétiquement en raison de facteurs environnementaux et/ou diététiques et ainsi favoriser l’inflammation intestinale. / Many studies have reported an imbalance of bacterial flora in patients with inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), defined as a dysbiosis, and resulting in an increase in potentially pathogenic bacteria versus a decrease in beneficial bacteria. Previous studies have highlighted the presence of pathogenic strains of E. coli in patients with CD. These strains belong to the pathovar Adherent Invasive E. coli (AIEC) and are characterized by their ability to adhere and invade intestinal epithelial cells, to survive and to multiply in macrophages by inducing an intense synthesis of TNF. In recent years, many studies established a link between AIEC pathovar and CD. Many of these studies have been performed on biopsies of patients with CD. And although the mechanisms of pathogenicity and virulence of the AIEC strain are clearly determined, there are no in-depth studies on the prevalence of AIEC in feces in IBD patients in comparison to healthy individuals. Thus, the goal of this thesis project is to better understand the involvement of AIEC pathovars in IBD at the luminal level. This thesis is based more precisely on the study of the prevalence of AIEC in feces of patients with IBD in comparison to healthy subjects, targeting different points: prevalence and detection of AIEC, their relative proportion compared to total E. coli flora, their invasion capacity, their phylogroup as well as their transmissibility. AIEC are found at luminal level in patients with CD but also in patients with UC, with detection of AIEC in 33% and 2% respectively. In addition, a higher prevalence of these pathovar is present in the feces of healthy individuals (51%) compared to patients with IBD. And when AIEC are present, both in IBD patients and in controls, they represent on average 20 to 30% of the E. coli flora. We have also been able to show that there are no significant differences in AIEC invasion scores in patients with IBD and in healthy subjects. Some AIEC strains, isolated in patients with CD and in healthy subjects, have been genetically characterized by pulsed-field gel electrophoresis. Different genetic profiles have been obtained attesting the high intra- and interindividual variability of AIEC strains. In conclusion, because of their high prevalence in healthy individuals, AIEC should be reconsidered as pathobionts, which defines a symbiont acquiring virulent properties in a genetically predisposed host due to environmental and / or dietary factors and thus promoting intestinal inflammation.

Introduction The fundamental concept for modern inflammatory bowel disease (IBD) treatment algorithm is an early induction of mucosal healing and its maintenance. Biological therapies are becoming mainstays of IBD therapy. It is however still unclear if there is a difference between Crohn’s disease (CD) and Ulcerative Colitis (UC) in time from diagnosis to stable maintenance treatment when biological treatment is introduced. Aim To investigate the comparative efficacy of biological agents in CD and UC by studying the time course when biological treatment is introduced. Methods Retrospective study of patients suffering from IBD at Falu Hospital, receiving a new start with biologics between 2015-01-01 and 2016-12-31. Remission rate after 3 months of induction therapy was analyzed. Subsequently, when 6 months passed without active disease, it was considered a stable remission. Results Through database extraction 58 patients were identified. A total of 52 % patients fulfilled the criteria for remission. Of patients with CD 49 % got in remission, whereof 33 % had treatment with infliximab, 48 % adalimumab and 19 % vedolizumab. Of patients with UC 60 % got in remission, whereof 33 % had treatment with infliximab and 67 % with adalimumab. Log rank test showed no significant difference in efficacy of biologics in patients suffering from CD or UC in time from diagnosis respective after initiation with biologics to stable maintenance treatment. ConclusionsIn this study patients with CD and UC responded equally to biological treatment.

According to the Crohn’s and Colitis Foundation of Canada, there is approximately 1 in every 200 individuals who is living with inflammatory bowel disease (IBD). Many of those living with IBD also need to have an ostomy. The literature on the effects IBD and an ostomy has on adolescents and young adults lacks consensus. Therefore, the purpose of this phenomenological study was to try to understand the lived experiences of adolescents and young adults (N=6) living with IBD and an ostomy. Sociodemographic information was collected, and the participants were interviewed in person using a semi-structured interview guide. The work of van Manen (1990) was used as a guide for data collection, analysis and interpretation of this study. Analysis revealed the essence of the adolescents’ and young adults’ lived experience as being “Concealing and Revealing the Self”. Three themes communicate the essence of their lived experience: (a) Uneasy feelings, (b) “It’s hard…”, and (c) A renewed sense of self. The needs of the adolescents and young adults, along with their recommendations to health care providers, are addressed. The study findings inform nurses in the areas of practice, education and research. Practice recommendations include being cognizant that these individuals need holistic care that addresses their psychological, psychosocial and physical needs. This study forms the basis for future research to explore some of the themes in greater detail, as well as a recommendation for a longitudinal study. / February 2008

This study assesses generic and disease-specific Health-Related Quality of Life (HRQOL) in children and adolescents with Inflammatory Bowel Disease (IBD). More specifically, the purpose of the study is to address the relationship between disease- specific indicators, both on a symptom-by-symptom basis and as a whole, to overall HRQOL. Self- and proxy-report versions of the Pediatric Quality of Life Inventory™ (PedsQL™) Generic Core Scales and the newly developed Pediatric Quality of Life Inventory™ Gastrointestinal Symptoms Module were administered to 187 parent-child dyads at ten study sites across the United States. Disease-specific indicators included: stomach pain, stomach upset, trouble swallowing, heartburn and reflux, gas and bloating, constipation, and diarrhea. It was hypothesized that caregiver- and child-reported disease-specific HRQOL would be positively correlated with generic HRQOL, and that physical disease-specific indicators would contribute the greatest variance in total generic HRQOL scores, for both self and proxy report. Results confirmed the hypothesis that disease-specific HRQOL would be positively correlated with generic HRQOL for children and caregivers. Multivariate regression results revealed that the Stomach Pain and Hurt, Worry, Medicines, and Communication scales contributed the most variance to overall HRQOL scores for children. The same analysis performed for parent ratings yielded one statistically significant scale: Worry. In essence, intervention efforts aimed at reducing the influence of worry and anxiety may prove more effective in improving HRQOL outcomes than interventions targeting reduction of physical symptoms.

According to the Crohn’s and Colitis Foundation of Canada, there is approximately 1 in every 200 individuals who is living with inflammatory bowel disease (IBD). Many of those living with IBD also need to have an ostomy. The literature on the effects IBD and an ostomy has on adolescents and young adults lacks consensus. Therefore, the purpose of this phenomenological study was to try to understand the lived experiences of adolescents and young adults (N=6) living with IBD and an ostomy. Sociodemographic information was collected, and the participants were interviewed in person using a semi-structured interview guide. The work of van Manen (1990) was used as a guide for data collection, analysis and interpretation of this study. Analysis revealed the essence of the adolescents’ and young adults’ lived experience as being “Concealing and Revealing the Self”. Three themes communicate the essence of their lived experience: (a) Uneasy feelings, (b) “It’s hard…”, and (c) A renewed sense of self. The needs of the adolescents and young adults, along with their recommendations to health care providers, are addressed. The study findings inform nurses in the areas of practice, education and research. Practice recommendations include being cognizant that these individuals need holistic care that addresses their psychological, psychosocial and physical needs. This study forms the basis for future research to explore some of the themes in greater detail, as well as a recommendation for a longitudinal study.